Adult SMA Research and Clinical Hub

Adult SMA REACH is a data collection study aiming to gain a better understanding of the impact of standards of care and new treatments on the natural history of Spinal Muscular Atrophy (SMA). This study is sponsored by The Newcastle upon Tyne Hospitals NHS Foundation Trust. Adult SMA REACH is funded by Biogen and Roche. Currently, there are three drug treatments available for SMA in the UK: Zolgensma, Nusinersen and Risdiplam. Zolgensma is the only approved drug - Nusinersen and Risdiplam are currently available as part of Managed Access Agreements (MAA).

NCT Number	NCT06978985
Lead Sponsor	Newcastle-upon-Tyne Hospitals NHS Trust Collaborators: Newcastle University, John Walton Muscular Dystrophy Research Centre, Biogen, Roche Products Limited
Conditions	Spinal Muscular Atrophy (SMA)
Enrollment	600 participants
Start Date	2022-07-29
Primary Completion	2027-04-30 (estimated)
Study Completion	2027-04-30 (estimated)
Updated on ClinicalTrials.gov	2025-05-18